Anti-Rheumatic Rx
Mrinalini Dey DrMiniDey
4 years 11 months ago
Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use.
Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer.
#ACR20 @RheumNow https://t.co/hNS600Pndr
Eric Dein ejdein1
4 years 11 months ago
How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 11 months ago
Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow
Peter Nash drpnash
4 years 11 months ago
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis https://t.co/DLGFcDqrus #RA #pain Pain sensitization a management issue - disease control minor benefit
The RECIPE Study - MMF in Refractory Gout: Dr. Jack Cush
Dr. Jack Cush previews the RECIPE study, wherein MMF is used to blunt the immunogenicity of pegloticase (abstract #0952 presented at the ACR 2020 annual meeting).
Antimalarials in Pre COVID-19 Era: Dr. Janet Pope
Dr. Pope discusses abstract #0002 presented at the #ACR20 annual meeting.
Richard Conway RichardPAConway
4 years 11 months ago
#ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
QD Clinic - Running out of Options
Difficult RA with Serious Infections and Limited options
Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.
In this compilation from the past week we talk about
- HIV and arthritis
- Hyperuricemia in PsA
- An odd kind of dermatomyositis
- Running out of options in Difficult RA
Listen here or on your podcast program in your car.
The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.
Poster Hall